Advertisement


Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

Opportunities to Optimize Cancer Policies Panel Discussion

Amit Sanyal, MD: A Clinician’s Perspective

Advertisement

Advertisement



Nov
30
Today In Oncology
Inotuzumab Ozogamicin–Based Induction in Older Patients With Philadelphia Chromosome–Negative B-Cell–Precursor ALL
Novel AI Model May Predict Nonsmokers at High Risk for Lung Cancer
Ultraprocessed Food May Heighten Risk of Head and Neck Cancer and Esophageal Adenocarcinoma
Trastuzumab Plus Gemcitabine/Cisplatin in Advanced HER2-Positive Biliary Tract Adenocarcinoma
Incidence of Breast Cancer After False-Positive Mammography
View More 
Advertisement
© 2023 HSP News Service, L.L.C.
Designed by Harborside